Selected research
Market Structure
Global NGAL Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global NGAL Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of NGAL Antibody include Thermo Fisher Scientific, Abcam, Hytest, Enzo Life Sciences, Biorbyt, Proteintech, Biomatik, Bio-Techne and MyBioSource, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global NGAL Antibody market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of NGAL Antibody and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents NGAL Antibody revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the NGAL Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
NGAL Antibody Segment by Company
Thermo Fisher Scientific
Abcam
Hytest
Enzo Life Sciences
Biorbyt
Proteintech
Biomatik
Bio-Techne
MyBioSource
GenScript
Bioss
BioNC
NGAL Antibody Segment by Type
Monoclonal Antibody
Polyclonal Antibody
NGAL Antibody Segment by Application
Clinic
Scientific Research
NGAL Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGAL Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NGAL Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGAL Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of NGAL Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NGAL Antibody industry.
Chapter 3: Detailed analysis of NGAL Antibody companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NGAL Antibodyrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibody
- Polyclonal Antibody
Applications
- Clinic
- Scientific Research
Companies covered
- Thermo Fisher Scientific
- Abcam
- Hytest
- Enzo Life Sciences
- Biorbyt
- Proteintech
- Biomatik
- Bio-Techne
- MyBioSource
- GenScript
- Bioss
- BioNC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global NGAL Antibody Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Monoclonal Antibody
- 1.2.3 Polyclonal Antibody
- 1.3 Market Analysis by Application
- 1.3.1 Global NGAL Antibody Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Clinic
- 1.3.3 Scientific Research
- 1.4 Global Market Growth Prospects
- 1.5 Global NGAL Antibody Growth Trends by Region
- 1.5.1 Global NGAL Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 NGAL Antibody Market Size by Region (2021-2026)
- 1.5.3 NGAL Antibody Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global NGAL Antibody Market Dynamics
- 2.1 NGAL Antibody Industry Trends
- 2.2 NGAL Antibody Industry Drivers
- 2.3 NGAL Antibody Industry Opportunities and Challenges
- 2.4 NGAL Antibody Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global NGAL Antibody Revenue by Company (2021-2026)
- 3.2 Global NGAL Antibody Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global NGAL Antibody Key Company Head office and Area Served
- 3.4 Global NGAL Antibody Company, Product Type & Application
- 3.5 Global NGAL Antibody Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global NGAL Antibody Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 NGAL Antibody Players Market Share by Revenue in 2025
- 3.6.3 2025 NGAL Antibody Tier 1, Tier 2, and Tier 3
4 NGAL Antibody Market by Type
- 4.1 Global NGAL Antibody Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global NGAL Antibody Market Size by Type (2021-2032)
- 4.3 Global NGAL Antibody Market Size Share by Type (2021-2032)
5 NGAL Antibody Market by Application
- 5.1 Global NGAL Antibody Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global NGAL Antibody Market Size by Application (2021-2032)
- 5.3 Global NGAL Antibody Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Thermo Fisher Scientific
- 6.1.1 Thermo Fisher Scientific Company Information
- 6.1.2 Thermo Fisher Scientific Business Overview
- 6.1.3 Thermo Fisher Scientific NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Thermo Fisher Scientific NGAL Antibody Product Portfolio
- 6.1.5 Thermo Fisher Scientific Recent Developments
- 6.2 Abcam
- 6.2.1 Abcam Company Information
- 6.2.2 Abcam Business Overview
- 6.2.3 Abcam NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Abcam NGAL Antibody Product Portfolio
- 6.2.5 Abcam Recent Developments
- 6.3 Hytest
- 6.3.1 Hytest Company Information
- 6.3.2 Hytest Business Overview
- 6.3.3 Hytest NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Hytest NGAL Antibody Product Portfolio
- 6.3.5 Hytest Recent Developments
- 6.4 Enzo Life Sciences
- 6.4.1 Enzo Life Sciences Company Information
- 6.4.2 Enzo Life Sciences Business Overview
- 6.4.3 Enzo Life Sciences NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Enzo Life Sciences NGAL Antibody Product Portfolio
- 6.4.5 Enzo Life Sciences Recent Developments
- 6.5 Biorbyt
- 6.5.1 Biorbyt Company Information
- 6.5.2 Biorbyt Business Overview
- 6.5.3 Biorbyt NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Biorbyt NGAL Antibody Product Portfolio
- 6.5.5 Biorbyt Recent Developments
- 6.6 Proteintech
- 6.6.1 Proteintech Company Information
- 6.6.2 Proteintech Business Overview
- 6.6.3 Proteintech NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Proteintech NGAL Antibody Product Portfolio
- 6.6.5 Proteintech Recent Developments
- 6.7 Biomatik
- 6.7.1 Biomatik Company Information
- 6.7.2 Biomatik Business Overview
- 6.7.3 Biomatik NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Biomatik NGAL Antibody Product Portfolio
- 6.7.5 Biomatik Recent Developments
- 6.8 Bio-Techne
- 6.8.1 Bio-Techne Company Information
- 6.8.2 Bio-Techne Business Overview
- 6.8.3 Bio-Techne NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Bio-Techne NGAL Antibody Product Portfolio
- 6.8.5 Bio-Techne Recent Developments
- 6.9 MyBioSource
- 6.9.1 MyBioSource Company Information
- 6.9.2 MyBioSource Business Overview
- 6.9.3 MyBioSource NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 MyBioSource NGAL Antibody Product Portfolio
- 6.9.5 MyBioSource Recent Developments
- 6.10 GenScript
- 6.10.1 GenScript Company Information
- 6.10.2 GenScript Business Overview
- 6.10.3 GenScript NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 GenScript NGAL Antibody Product Portfolio
- 6.10.5 GenScript Recent Developments
- 6.11 Bioss
- 6.11.1 Bioss Company Information
- 6.11.2 Bioss Business Overview
- 6.11.3 Bioss NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Bioss NGAL Antibody Product Portfolio
- 6.11.5 Bioss Recent Developments
- 6.12 BioNC
- 6.12.1 BioNC Company Information
- 6.12.2 BioNC Business Overview
- 6.12.3 BioNC NGAL Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 BioNC NGAL Antibody Product Portfolio
- 6.12.5 BioNC Recent Developments
7 North America
- 7.1 North America NGAL Antibody Market Size (2021-2032)
- 7.2 North America NGAL Antibody Market Size by Type
- 7.2.1 North America NGAL Antibody Market Size by Type (2021-2026)
- 7.2.2 North America NGAL Antibody Market Size by Type (2027-2032)
- 7.2.3 North America NGAL Antibody Market Share by Type (2021-2032)
- 7.3 North America NGAL Antibody Market Size by Application
- 7.3.1 North America NGAL Antibody Market Size by Application (2021-2026)
- 7.3.2 North America NGAL Antibody Market Size by Application (2027-2032)
- 7.3.3 North America NGAL Antibody Market Share by Application (2021-2032)
- 7.4 North America NGAL Antibody Market Size by Country
- 7.4.1 North America NGAL Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America NGAL Antibody Market Size by Country (2021-2026)
- 7.4.3 North America NGAL Antibody Market Size by Country (2027-2032)
- 7.4.4 North America NGAL Antibody Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe NGAL Antibody Market Size (2021-2032)
- 8.2 Europe NGAL Antibody Market Size by Type
- 8.2.1 Europe NGAL Antibody Market Size by Type (2021-2026)
- 8.2.2 Europe NGAL Antibody Market Size by Type (2027-2032)
- 8.2.3 Europe NGAL Antibody Market Share by Type (2021-2032)
- 8.3 Europe NGAL Antibody Market Size by Application
- 8.3.1 Europe NGAL Antibody Market Size by Application (2021-2026)
- 8.3.2 Europe NGAL Antibody Market Size by Application (2027-2032)
- 8.3.3 Europe NGAL Antibody Market Share by Application (2021-2032)
- 8.4 Europe NGAL Antibody Market Size by Country
- 8.4.1 Europe NGAL Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe NGAL Antibody Market Size by Country (2021-2026)
- 8.4.3 Europe NGAL Antibody Market Size by Country (2027-2032)
- 8.4.4 Europe NGAL Antibody Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China NGAL Antibody Market Size (2021-2032)
- 9.2 China NGAL Antibody Market Size by Type
- 9.2.1 China NGAL Antibody Market Size by Type (2021-2026)
- 9.2.2 China NGAL Antibody Market Size by Type (2027-2032)
- 9.2.3 China NGAL Antibody Market Share by Type (2021-2032)
- 9.3 China NGAL Antibody Market Size by Application
- 9.3.1 China NGAL Antibody Market Size by Application (2021-2026)
- 9.3.2 China NGAL Antibody Market Size by Application (2027-2032)
- 9.3.3 China NGAL Antibody Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia NGAL Antibody Market Size (2021-2032)
- 10.2 Asia NGAL Antibody Market Size by Type
- 10.2.1 Asia NGAL Antibody Market Size by Type (2021-2026)
- 10.2.2 Asia NGAL Antibody Market Size by Type (2027-2032)
- 10.2.3 Asia NGAL Antibody Market Share by Type (2021-2032)
- 10.3 Asia NGAL Antibody Market Size by Application
- 10.3.1 Asia NGAL Antibody Market Size by Application (2021-2026)
- 10.3.2 Asia NGAL Antibody Market Size by Application (2027-2032)
- 10.3.3 Asia NGAL Antibody Market Share by Application (2021-2032)
- 10.4 Asia NGAL Antibody Market Size by Country
- 10.4.1 Asia NGAL Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia NGAL Antibody Market Size by Country (2021-2026)
- 10.4.3 Asia NGAL Antibody Market Size by Country (2027-2032)
- 10.4.4 Asia NGAL Antibody Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa NGAL Antibody Market Size (2021-2032)
- 11.2 South America, Middle East & Africa NGAL Antibody Market Size by Type
- 11.2.1 South America, Middle East & Africa NGAL Antibody Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa NGAL Antibody Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa NGAL Antibody Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa NGAL Antibody Market Size by Application
- 11.3.1 South America, Middle East & Africa NGAL Antibody Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa NGAL Antibody Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa NGAL Antibody Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa NGAL Antibody Market Size by Country
- 11.4.1 South America, Middle East & Africa NGAL Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa NGAL Antibody Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa NGAL Antibody Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa NGAL Antibody Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst